Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
Gene Therapy Promise | Benitec Biopharma's BB-301 shows encouraging results in OPMD trial, with consistent improvements in swallowing capability and patient-reported outcomes |
Clinical Milestones | Explore the company's progress as it advances to the high-dose cohort, with potential updates expected in Q4 2025 that could significantly impact stock performance |
Financial Fortitude | Learn about Benitec's robust liquidity position, with a current ratio of 14.8 and recent $30 million capital raise, supporting ongoing clinical development |
Market Potential | Analyst price targets range from $17 to $35, suggesting significant upside potential as Benitec's gene therapy platform shows promise for treating rare diseases |
Metrics to compare | BNTC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBNTCPeersSector | |
---|---|---|---|---|
P/E Ratio | −10.9x | −3.7x | −0.5x | |
PEG Ratio | −0.57 | 0.01 | 0.00 | |
Price/Book | 2.9x | 3.3x | 2.6x | |
Price / LTM Sales | - | 166.2x | 3.3x | |
Upside (Analyst Target) | 155.5% | 133.0% | 45.4% | |
Fair Value Upside | Unlock | 0.9% | 7.7% | Unlock |